Metoclopramide, a dopamine D2 receptor antagonist and mixed serotonin 5-hydroxytryptamine (HT) 3 receptor antagonist and 5-HT4 receptor agonist, is a prokinetic and the only FDA-approved medication for gastroparesis, highlighting the need for more therapeutic options. This evidence concerns the gene DRD2 and gastroparesis.